Blog
Published September 17, 2024
What does orchestration mean for a brand?
True orchestration considers a customer’s preferences before communicating with them. Learnings from past interactions and outcomes are used to identify the most relevant action to lead to a rewarding experience for both the customer and the brand. Orchestration can be defined as all channels learning from each other to create better “surround sound” for the customer.
Orchestration for a brand means that you have a thoughtfully-built decision engine that can process historical customer…
Read Now
Blog
Published September 12, 2024
The short answer is yes, by powering process automation with GenAI. It’s an approach that hasn’t received as much attention as other GenAI use cases within life sciences, but the results can be very powerful.
To illustrate its power, we’ll examine a case study on identifying debarred healthcare professionals (HCPs).
Why is it important to identify debarred HCPs?
Pharmaceutical companies are mandated to cease all forms of engagement with debarred healthcare professionals (HCPs) in the U.S.
Compliance entails identifying and…
Read Now
Webinars
Available On Demand
Life sciences leaders are faced with a firehose of news, events and data. As the advancement of technology provides ever greater access to information and resources become more constrained, the risk of becoming inundated and bogged down in the details presents an ongoing challenge for Competitive Intelligence (CI) teams and their stakeholders. CI teams that can filter out the noise and focus on the things that are really important end up saving significant time and resources and can better influence brand…
Watch Now
Blog
Published September 5, 2024
First, what does “omnichannel” mean in life sciences?
Omnichannel is a customer-centric strategy leveraging technology, data and analytics across functions to optimize cross-channel engagement.
So, why is it so hard to achieve effective customer engagement impact?
There are some companies that have achieved intended outcomes when deploying “Omnichannel” and embarking on a “digital transformation” – but many have found it much harder than expected.
The challenges are driven by three areas of misperception:
The simplistic view that omnichannel is a…
Read Now
Webinars
Available On Demand
Working at the cutting edge of pricing and market access for innovative therapies launched over the last decade, Trinity Life Sciences has seen new diseases, technologies and decision drivers emerge. These have demanded the innovation and testing of new methods and concepts for communicating value to healthcare payers.
In this webinar, we will briefly review the core, timeless principles of value communication. We will then dive into the challenges that each innovation has created for industry teams developing value strategy and value communication tools. We will review…
Watch Now
Webinars
Available On Demand
Today’s “New Normal” is a constant effort to optimally reach and engage rapidly changing customers by applying novel approaches to democratizing and transforming data. Join Nancy Phelan, SVP & Head of Customer Engagement (CE) at Trinity Life Sciences for an in-depth investigation of CE models that work, including insights from a new landscape study on the drivers and obstacles to achieving success when applying an omnichannel strategy. Attendees will gain insights and data to help lead their organizations and teams…
Watch Now
White Papers
Experts at Trinity Life Sciences interact with the inner workings of pharma from many perspectives as they engage with teams across life sciences organizations.
A common observation is that teams are working in silos: often unaware of what other teams are doing, sometimes pulling in different directions and frequently experiencing frustrations.
Internally, siloed working can create delays, unnecessary budget burn and re-work. Externally, it can result in negative coverage decisions or market underperformance, which ultimately impacts the patient. In some…
Read Now
Blog
Published August 16, 2024
Yesterday, CMS released the results of the first round of “negotiated” prices for the Inflation Reduction Act (IRA).1
The IRA is a historical landmark legislation for the pharmaceutical industry, and the results from these “negotiations” involving 10 of the top Medicare Part D drugs in terms of spend were eagerly awaited by many.
Immediately, both the Biden Administration and the Harris-Walz campaign commented on the public savings that these “negotiations” have generated, claiming this as a “beginning”.
“Medicare has reached…
Read Now
Webinars
Available On Demand
The second webinar in our “Next Era in U.S. Healthcare Policy & Access” series looks at the evolving healthcare policy landscape from a different perspective. Join us as we explore how U.S. policy changes are impacting health plans, how health plan decision-making needs to adapt, and what this means for biopharma companies. The webinar will feature an engaging panel discussion hosted by Max Hunt, Partner at Trinity Life Sciences, with special guests Stephen George and Matthew Hayes, clinical and actuarial…
Watch Now
Case Studies
Trinity AI’s GenAI-powered process automation solution to improve data operations efficiency won QC Data Management Solution of the Year in the 2024 BioTech Breakthrough Awards.
Explore Trinity AI
The Situation
Pharmaceutical companies are mandated to cease all forms of engagement with debarred healthcare professionals (HCPs) in the U.S. Compliance entails identifying and flagging HCPs from lists periodically released by government agencies. These agencies also issue exclusion notices that call out HCPs whomight be confused with debarred HCPs due to similar…
Read Now
